Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Gattermann

Showing results (91-100 of 158) with videos related to

Pageof 16
Sort By:
Onkologie|September 13, 2008
Myelodysplastic syndromes: aspects of current medical care and economic considerations in GermanyNorbert Gattermann, Wolf-Karsten Hofmann, Axel Meessen, et al.
Blood Transfusion = Trasfusione Del Sangue|August 9, 2012
Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemiasVip Viprakasit, Norbert Gattermann, Jong Wook Lee, et al.
BMJ Open|April 9, 2025
Virtual Reality and Sound Intervention under Chemotherapy (ViSu): study protocol for a three-arm randomised-controlled trialSteffen Holsteg, Luisa Ernsten, Nora K Schaal, et al.
Leukemia Research|December 22, 2009
Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromesAkira Matsuda, Ulrich Germing, Itsuro Jinnai, et al.
Cancers|February 24, 2024
Infectious Complications in Patients with Myelodysplastic Syndromes: A Report from the Düsseldorf MDS RegistryAnnika Kasprzak, Julia Andresen, Kathrin Nachtkamp, et al.
Haematologica|May 30, 2008
Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arraysLi Wang, Carrie Fidler, Nandita Nadig, et al.
Clinical Epigenetics|June 19, 2012
Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acidAndrea Kuendgen, Gesine Bug, Oliver G Ottmann, et al.
Hematological Oncology|May 2, 2008
Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf studyFrank Neumann, Judith Markett, Roland Fenk, et al.
Cancer|June 10, 2011
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromesLewis R Silverman, Pierre Fenaux, Ghulam J Mufti, et al.
European Journal of Haematology|January 21, 2015
Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromesJennifer Schemenau, Stephan Baldus, Martin Anlauf, et al.
Pageof 16

Showing results (91-100 of 158) with videos related to

Sort By:
Pageof 16
Onkologie|September 13, 2008
Myelodysplastic syndromes: aspects of current medical care and economic considerations in GermanyNorbert Gattermann, Wolf-Karsten Hofmann, Axel Meessen, et al.
Blood Transfusion = Trasfusione Del Sangue|August 9, 2012
Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemiasVip Viprakasit, Norbert Gattermann, Jong Wook Lee, et al.
BMJ Open|April 9, 2025
Virtual Reality and Sound Intervention under Chemotherapy (ViSu): study protocol for a three-arm randomised-controlled trialSteffen Holsteg, Luisa Ernsten, Nora K Schaal, et al.
Leukemia Research|December 22, 2009
Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromesAkira Matsuda, Ulrich Germing, Itsuro Jinnai, et al.
Cancers|February 24, 2024
Infectious Complications in Patients with Myelodysplastic Syndromes: A Report from the Düsseldorf MDS RegistryAnnika Kasprzak, Julia Andresen, Kathrin Nachtkamp, et al.
Haematologica|May 30, 2008
Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arraysLi Wang, Carrie Fidler, Nandita Nadig, et al.
Clinical Epigenetics|June 19, 2012
Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acidAndrea Kuendgen, Gesine Bug, Oliver G Ottmann, et al.
Hematological Oncology|May 2, 2008
Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf studyFrank Neumann, Judith Markett, Roland Fenk, et al.
Cancer|June 10, 2011
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromesLewis R Silverman, Pierre Fenaux, Ghulam J Mufti, et al.
European Journal of Haematology|January 21, 2015
Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromesJennifer Schemenau, Stephan Baldus, Martin Anlauf, et al.
Pageof 16